PPARGC1A and inflammatory bowel disease: Pharmacological activation of PGC-1α also showed a protective effect against IBD by reducing the expression of inflammatory cytokines such as interleukin (IL)-1β, IL-18, and TNF-α in IBD mice, as well as macrophage infiltration in colon tissue.